• MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Rheumatology Network. All rights reserved.

Osteonecrosis Linked to Corticosteroid Use in SLE

August 14, 2018
Gregory M. Weiss, MD

This complication occurs in up to 44% of patients with systemic lupus erythematosus.

Reference1. Hussein S, Suitner M, Béland-Bonenfant S, et al. Monitoring of osteonecrosis in systemic lupus erythematosus patients: a systematic review and metaanalysis. J Rheumatol. 2018 Jul 1. pii: jrheum.170837. doi:10.3899/jrheum.170837. [Epub ahead of print]

Hussein and colleagues in Canada have discovered a potentially strong association between corticosteroid use in systemic lupus erythematosus (SLE) and osteonecrosis.1 Scroll through the slides for the details of the study and the take-home points for physicians.

(Image credit: ©ImagePointFr/Shutterstock.com)

SLE, systemic lupus erythematosus.

SLE, systemic lupus erythematosus.

SLE, systemic lupus erythematosus.

SLE, systemic lupus erythematosus.

SLE, systemic lupus erythematosus.

Note that osteonecrosis was not associated with any other drug nor with any specific laboratory finding.

PreviousNext

Related Content:

LupusJoint/Bone Health
Neonatal Lupus Erythematosus Risk Not Linked to Ethnicity
Poor Social Determinants Linked to Worse Care and Outcomes for Patients With Lupus
Rheumatology Network's Top 5: April 2, 2021